Tagged with r

ACP PHARMA The group has significantly invested in Poland. Are you today generally satisfied with the initial and follow up investments from Mediq in the country? The group has been present in Poland for over ten years. From the beginning, Mediq NV looked for tenders in Poland, and bought a few companies…

Alliance Healthcare Russia You took over this organization just three months ago, having previously headed businesses in industries as diverse as retail, food, and automobiles. What drew you to Alliance Healthcare Russia? Do you find similarities between this job and your previous positions? When I decided to leave my former position, I decided…

Roche Thailand Dr Ammelburg, you have been working for Roche for more than 25 years now, time essentially spent between your home country Germany and Thailand. After more than 10 years spent here, what would you consider to be the main specificities of the Thai Pharma industry? The Thai market is not…

Zydus Group You have very successfully executed a vision that you have had for the company since it was a 200 Rs Cr turnover, India-focused enterprise 15 years ago. You have had 18-fold growth since then, and you are set to achieve 1Bn USD in turnover for the first time this March!…

Association of the Russian Pharmaceutical Manufacturers (ARPM) The ARPM was founded in 2002, and you were its director from 2002-2004, before leaving for a post at the Roszdravnadzor. You’ve since rejoined as director since 2007. The organization was originally founded as a unifying force amongst Russian national manufacturers, and has now grown to encompass several foreign members.…

Nucleus Network Please introduce Nucleus Network and the role it plays in the Australian pharmaceutical sector. Nucleus Network is an early-phase clinical research business, and is somewhat unique, as it is a not for profit organization, being wholly-owned by the Baker IDI Heart and Diabetes research institute. Originally, Nucleus Network was set…

Theraskin Brazil When we met you in 2007, as the head of the former Igefarma, the company was undergoing a transition – from branded generics into dermocosmetics and women’s health. But since that period of transition, there has been quite a transition again! Could you bring our readers up to speed? Since…

Amgen Australia What impact have the PBS reforms had on Amgen in Australia? From a company perspective, biotechnology companies exist in a competitive space. They have predominantly niche medicines with significant competitive advantages and tend to be on their own in a certain clinical space and treatment paradigm. Amgen sells very few…

Pharmaceutical Industry Council (PIC) 2006 marked a major milestone, with the Pharmaceutical Industry Action Agenda transformed from a Government-industry initiative into an industry-driven agenda, and the resulting creation of the Pharmaceutical Industry Council (PIC). Would you please introduce the organization, and tell us about the main milestones and achievements since you began your tenure…

Generic Medicines Industry Association To begin, would you please introduce GMIA to Pharmaceutical Executive readers? The GMIA is an industry organization. Its six members are: Alphapharm, Apotex, Genepharm, Hospira, Sandoz and Sigma. The GMiA is the lobby group for the generic medicines industry in Australia, working with all relevant stakeholders, such as government, prescribers,…

Allergan How have PBS reforms impacted Allergan in Australia? The PBS is a very good system that provides Australians with equity of access and has worked well in the country for many years. Once a therapeutic is approved and funded, Australia has one of the highest penetration rates around the world.…

Alphapharm Alphapharm recently celebrated its 25th anniversary. In light of this significant milestone, would you give us a brief introduction to the company? Alphapharm started in 1982 in Brisbane with a handful of products and a handful of people. Twenty-five years later, we celebrated our silver anniversary, coming from nowhere to…